Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Diabetes after transplantation].

Antoine Durrbach1

  • 1Groupement hospitalier universitaire Sud, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France. durrbach@wanadoo.fr

Nephrologie & Therapeutique
|March 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SARS-CoV-2 mRNA XBB1.5 vaccine immunogenicity in kidney transplant recipients.

Virology journal·2026
Same author

Optimizing risk-benefit in highly sensitized kidney recipient antigen delisting increasing donor access.

Kidney international·2026
Same author

The inhibitory receptor NKG2A is expressed on T-cells during BKPyVANephropathy.

Frontiers in immunology·2026
Same author

Impact of Corticosteroid-Free Regimen on Interstitial Fibrosis Following Kidney Transplantation.

Kidney international reports·2025
Same author

BKPyV-specific T-cell Exhaustion in Kidney Transplant Recipients: Targeting Inhibitory Receptors Improves Their Functionality.

Transplantation·2025
Same author

Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future.

Transplant international : official journal of the European Society for Organ Transplantation·2025

New-onset diabetes after transplantation is common and increases cardiovascular risk. Early intervention and optimized immunosuppression, especially for hepatitis C-positive patients, are crucial for managing this condition.

Area of Science:

  • Nephrology
  • Transplantation Medicine
  • Endocrinology

Context:

  • Post-transplantation diabetes mellitus (PTDM) incidence rises with time, affecting up to 20% of patients within 10 years.
  • PTDM significantly elevates cardiovascular complication and mortality risks in transplant recipients.
  • Key PTDM risk factors include hepatitis C seropositivity (HCV+), ethnicity, obesity, and immunosuppressants like corticoids and calcineurin inhibitors.

Purpose:

  • To highlight the increasing incidence and severe consequences of PTDM in European transplant recipients.
  • To identify major risk factors contributing to PTDM development.
  • To discuss emerging treatment strategies aimed at mitigating PTDM risk and incidence.

Summary:

  • PTDM incidence increases with post-transplantation delay, posing significant cardiovascular risks.

Related Experiment Videos

  • Risk factors include HCV+, ethnicity, obesity, and specific immunosuppressive drugs (corticoids, calcineurin inhibitors).
  • New strategies involve early corticoid discontinuation and optimized immunosuppression (e.g., mycophenolate mofetil, drug conversions).

    • Impact:

    • Emphasizes the need for prompt PTDM diagnosis and management to reduce mortality.
    • Highlights vulnerable populations, particularly HCV+ patients, requiring tailored therapeutic approaches.
    • Stresses the importance of individualized treatment strategies balancing PTDM management with cardiovascular risk and graft survival.